Protara Therapeutics, Inc.

NasdaqGM TARA

Protara Therapeutics, Inc. Interest Coverage Ratio for the Trailing 12 Months (TTM) ending September 30, 2024: -66.79

Protara Therapeutics, Inc. Interest Coverage Ratio is -66.79 for the Trailing 12 Months (TTM) ending September 30, 2024, a 90.05% change year over year. Interest coverage ratio assesses earnings' ability to cover interest expenses; higher ratios signal lower risk.

Protara Therapeutics, Inc. Interest Coverage Ratio for the Trailing 12 Months (TTM) ending September 30, 2023 was -671.05, a -1,785.79% change year over year.
Protara Therapeutics, Inc. Interest Coverage Ratio for the Trailing 12 Months (TTM) ending September 30, 2022 was -35.58, a 2.48% change year over year.
Protara Therapeutics, Inc. Interest Coverage Ratio for the Trailing 12 Months (TTM) ending September 30, 2021 was -36.49.

Key data

Date	Interest Coverage Ratio	Debt to Equity Ratio	Interest Expense To Sales	Inventory Turnover Ratio

NasdaqGM: TARA

Protara Therapeutics, Inc.

CEO	Mr. Jesse Shefferman
IPO Date	Oct. 22, 2014
Location	United States
Headquarters	345 Park Avenue South
Employees	26
Sector	Healthcare
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.

Key trends

Past 5 years